After decades of tragic fallout from the myth that the abortion pill is “safer than Tylenol,” nearly two dozen attorneys general have sent a letter to the U.S. Department of Health and Human Services (HHS) asking them to reinstate the pre-2016 safety requirements that were weakened by pro-abortion administrations.According to the letter, the attorneys general are calling upon HHS Secretary Robert F. Kennedy, Jr. and FDA head, Martin Makary to restore safeguards for the pills that were scrapped by the Obama and Biden administrations.
"Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of 'safe' and 'effective,'" the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPC), a Washington, D.C.-based advocacy group.
The EPPC study found that the pill causes 1 in 10 patients to experience a “serious adverse event,” including hemorrhage, emergency room visits and ectopic pregnancy.
"Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them," the attorneys general wrote. "And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died."
In light of these risks, and because chemical abortions account for more than half of all abortions in the US, the letter is asking the FDA that if they are unable to reinstate the 2011 safeguards for mifepristone, that the drug be withdrawn from the market until it can complete a review and decided on a course of action.
"The FDA’s removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA’s dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised," the letter concludes.
Secretary Kennedy’s promise was ascertained during a Senate Committee meeting this past spring when the Secretary said he found the new data on mifepristone to be “alarming” and indicated that at the very least, the label should be changed.
“I’ve asked Marty Makary at the FDA to do a complete review and report back,” Kennedy said, and promised to send a recommendation to President Donald Trump based on their findings.
Mifepristone has been the subject of controversy for years, from its fast-tracked approval during the Clinton Administration to the gradual relaxing of safeguards for political rather than scientific reasons.
In addition, as Live Action News reports, women reporting to ERs as a result of abortion pill complications have been encouraged for decades to lie to doctors and staff about taking the pills. They are told to say they are having a miscarriage instead.
“Because prescribers 1) offload complications to ERs and 2) encourage women to lie, in addition to the fact that 3) the Obama FDA said reporting even serious non-fatal complications wasn’t necessary, this has made the abortion pill appear far safer than it actually is,” Live Action reports.
Let us pray that the long-hidden truth about the dangers of mifepristone, to both mother and child, may soon be brought into the light.
© All Rights Reserved, Living His Life Abundantly®/Women of Grace® http://www.womenofgrace.com
